Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AZ, Array Biopharma Cancer Program Advances | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AZ, Array Biopharma Cancer Program Advances

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Array BioPharma and AstraZeneca have selected a third compound for their small molecule MEK anti-cancer program, triggering a $1 million milestone payment by AstraZeneca. The second compound was selected in January 2006, also triggering a $1 million milestone to Array.  In December 2003, Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-142886 (AZD6244), for co-development and commercialization with AZ.  At that time, the companies established a collaboration for R&D of additional clinical candidates.  

According to Array, MEK is a critical enzyme at the intersection of several biological pathways, which regulates cell proliferation and survival as part of the Ras/Raf/MEK/ERK pathway. Constitutive activation of the Ras/Raf/MEK/ERK pathway has been implicated in many cancers, including lung, pancreatic, colon, melanoma and thyroid caused by cancer-associated, mutational activation of bRAF and Ras proteins. MEK inhibition is seen as an attractive anti-cancer strategy as it has the potential to block inappropriate signal transduction regardless of the upstream position of the oncogenic aberration.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters